Cardiology

Neurologic events following TAVR are linked to worse survival outcomes. Research highlights that strokes pose the greatest mortality risk.

The ESC 2024 TIGHT-K trial found that relaxed potassium control is just as effective as tight control for preventing atrial fibrillation post-CABG surgery.

A single-pill with four blood pressure drugs is more effective than a three-drug combo for resistant hypertension, per ESC Congress 2024.

ESC 2024: The SHAM-PVI trial confirms that catheter ablation significantly reduces atrial fibrillation burden and improves quality of life compared to a sham treatment.

ESC 2024: OCT-guided PCI in complex lesions reduced cardiac risks by 38% and spontaneous MI by 64% versus angiography, according to the OCCUPI trial.

Atrial fibrillation screening using a 14-day wearable heart monitor patch significantly increased diagnoses compared to usual care, according to research presented at ESC 2024.

The PROTEUS trial, presented at ESC 2024, evaluated the effectiveness of AI in standardizing clinician decision-making during stress echocardiography for coronary artery disease

Presented at ESC 2024, vutrisiran, an RNAi therapeutic, significantly reduced mortality and cardiovascular events in patients with ATTR-CM.